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ABSTRACT   
Background: Ciprofloxacin is a fluorinated 4-quinolone or fluoroquinolone antibacterial with a 
wider spectrum of activity than nalidixic acid and more favorable pharmacokinetics allowing its 
use in systemic infections.  It  has  been  used  in  the  treatment  of  a  wide  range  of infections. 
Many  different  brands  and  dosage  forms  of  Ciprofloxacin hydrochloride are  available  in  the  
Sana
'
a market  that  places  health practitioners  in  a  dilemma  of  drug  substitution  in case  of  
non-availability  of  a  particular brand.  
Aim/Objective:  The aim of the present study was to evaluate the quality control of five brands of 
Ciprofloxacin hydrochloride tablets marketed and commonly prescribed in Sana
'
a city. The results 
and findings of the present study will be interpreted and discussed. 
Materials and methods: Five brands of Ciprofloxacin hydrochloride tablets (500 mg) were 
purchased from the retail pharmacy outlets and their pharmaceutical quality were assessed by using 
in-vitro tests as per the British Pharmacopoeia (BP) and unofficial standards as recommended by 
the manufacturers. The assessment of tablets included the evaluation of uniformity of weight, 
friability, hardens, disintegration time, dissolution test and assay content by UV 
spectrophotometric method. 
Results: All brands passed USP and BP standards in- vitro quality control tests prescribed for the 
tablets except hardens test but the all products were satisfactory for hardness. 
Conclusion: The results indicated that the overall quality of all tested Ciprofloxacin hydrochloride 
tablets brands was satisfactory as they met the requirements of the official and unofficial quality 
control tests.   
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1. Introduction 
Ciprofloxacin is a synthetic flouroquinolone derivative with broad spectrum antibacterial 
activity [1]. It is widely used in the treatment of urinary tract infections, lower respiratory tract 
infections, bacterial diarrhoea, skin and soft tissue infections, bone and joint infections, gonorrhea, 
and in surgical prophylaxis [2]. In most of the cases, it would appear that for treatment of above 
said infections, physicians prescribe ciprofloxacin as a first choice of drug. Ciprofloxacin (CIP) is 
flouroquinolone with fluorine at position 6 of naphthyridine ring. The chemical structure of 
ciprofloxacin is shown in Figure 1 [3]. 
                    
Figure 1. Chemical structure of ciprofloxacin. 
 
Quality control is all measures designed to ensure the output of uniform batches of drugs 
that conform to established specifications of identity, strength, purity, and other characteristics [4]. 
According to pharmaceutical manufacturers association of U.S. “quality is the sum of all the 
factors which contribute directly or indirectly to the safety, effectiveness and acceptability of the 
  
product” [5]. Also, quality control is the part of Good Manufacture Practice (GMP) that is 
concerned with sampling, specifications, testing, documentation and release procedures which 
ensure that the necessary and relevant tests are actually carried out and that the materials are not 
released for use, not products released for sale or supply, until their quality has been judged to be 
satisfactory [6]. 
A comprehensive evaluation, however, involves the determination of uniformity of weight, 
chemical content, friability, hardness, and disintegration tests along with dissolution rate. Drugs 
that are chemically and biopharmaceutically equivalent must be identical in strength, quality, and 
purity. The content uniformity, disintegration, and dissolution rates must be comparable [7]. 
The United States Pharmacopoeia [8] describes an HPLC method for CIPRO and CIPRO 
HCl assay in bulk, CIPRO injection, ophthalmic ointment, ophthalmic solution and tablets. Despite 
most methods presented in official compendia are physicochemical assays, these methods do not 
represent the potency of antimicrobials neither can predict the loss of activity. 
The aim of the present study is to evaluate the quality of different brands of Ciprofloxacin 
tablets. 
2. Materials and Methods  
2.1. Materials 
Comparative in-vitro quality control parameters between six commercially available tablet 
different brands of ciprofloxacin were purchased from the retail pharmacies in Sana
,
a, Yemen. All 
brands were studied through the evaluation of weight variation, drug content, hardness, friability, 
disintegration time and dissolution profile. All the tablet brands of ciprofloxacin were labeled to 
contain 500 mg of ciprofloxacin per tablet and coded as A, B, C, D, and E (table 1).  The study was 
done by performing various test procedures associated to assess the quality of tablets. USP and 
British pharmacopoeia were used as standard for the evaluation study. 
Table 1. Brands of Ciprofloxacin 
Code 
Brand 
Country of  
origin 
Strength  
in mg 
Batch  
number 
A Yemen 500 12669 
B Yemen 500 13219 
C Yemen 500 1991 
D India 500 1301 
E India 500 FD3175 
 
2.2. Methodology:   
Various analytical methods and tests are important for the development and manufacture of 
pharmaceutical formulations. The evaluation was done according to USP and BP standards. 
 
2.2.1. Weight Variation 
Twenty (20) tablets from each of the brands were weighed individually using an analytical 
weighing balance. The average weight for each brand as well as percentage deviations were 
calculated. 
2.2.2. Drug content  
The estimation of drug content for ciprofloxacin tablets was performed by crushing three tablets 
and quantity equivalent to 45 mg was taken and determined using 0.1M HCl using UV 
spectrophotometer at about 276 nm,  
  
2.2.3. Hardness Test  
A tablet was placed vertically on the Monsanto Hardness tester. The load was then applied along 
the radial axis of the tablet. The weight or load required for breaking the tablet was noted down. 
Similarly it was done for 10 tablets. 
2.2.4.Friability 
It was performed using Roche Friabilator, 10 tablets were weighed and placed in apparatus. The 
apparatus was rotated at a speed of 25 rpm. The apparatus was made to rotate for 4 min. The 
tablets were reweighed (W2) and compared with their initial weights and percentage friability was 
obtained.  Percentage friability was calculated as: 
           Percentage friability = [(W1–W2)/W1] x 100%. 
2.2.5. Disintegration Test 
Six (6) tablets from each brand were employed for this test in a freshly prepared medium, 0.1N 
HCl at 37
o
C using the BP disintegration apparatus.  The disintegration time was taken to be the 
time no particle remained on the basket of the system. 
2.2.6. Dissolution Test 
The dissolution test was carried out using USP apparatus II (paddle method) 5 in 6 replicates for 
each brand.  The dissolution medium was 900 mL 0.1N HCL which was maintained at 37± 0.5
o
C.   
In all the experiments  5  mL  of  dissolution  sample  was withdrawn  at  0,  10,  20,  and 30  min  
and  replaced  with  equal volume  of  dissolution  medium  to  maintain  sink  condition.  The 
sampling times were selected in due consideration for the short disintegration times.  Samples were 
filtered and assayed by ultraviolet spectrophotometry at 276 nm. The concentration of each sample 
was determined from a predetermined calibration curve for ciprofloxacin hydrochloride. 
2.2.7. Data processing and analysis  
After the completion of all test procedures data for all the individual tablets were recorded and 
separated on a different sheets according to the manufacturer. Finally, data were analyzed by using 
the above mentioned mathematical formula and MS-Excel®, 2007. 
3. Results and Discussion 
3.1 General aspect 
The present study was conducted to assess the quality of 500 mg ciprofloxacin tablets 
marketed in Sana’a Yemen. To achieve this purpose, four different pharmaceutical companies 
(brands) A, B, C, D, and E were used (see table 1). They were obtained from different retail 
pharmacies in Sana’a and then were subjected to a number of tests. A quality control study is very 
important to evaluate tablet properties. Different quality control parameters (e.g., weight variation, 
drug content uniformity, hardens, friability, disintegration time and dissolution tests) were 
performed to determine the differences among various conventional ciprofloxacin tablets   that are 
available in the Yemeni drug market. 
3.2. Average Weight and Weight Variation: 
Although the uniformity of weight does serve as a pointer to good manufacturing practice 
(GMP) as well as amount of the active pharmaceutical ingredients, especially for reproducibility of 
the product which is very essential for mass production of any product.  
The average weight and weight variation of the different brands of ciprofloxacin tablets 
tested are shown in Tables 3.1 and Fig.3.1. It was found that the average weight of different five 
brands tablets of ciprofloxacin tablets ranged from 679.3 mg  2.63 % (A brand) to 842.7 mg  
3.58 % (E brand), while the deviation from average weight for all product is not more than 3.58 %. 
  
Therefore, all the five brands tested in this study complied with the compendia specification for 
uniformity of weight which states that for tablets weighing more than 324 mg, weight of not more 
than 2 tablets should not differ from the average weight by more than 5% [9]. Thus, all brands 
passed the weight uniformity test set by USP. Also, the results indicate the use of different 
excipients with different weights. 
   
Table 2. Average weight, % deviation from average weight, content uniformity, and 
% deviation from content uniformity of different brands of ciprofloxacin tablets.     
Brands 
Average weight (mg) , 
% RSD   
Content uniformity (%),  
% RSD  
A 679.3 ± 2.63 98.10 % ± 2.2990 
B 758.3  ±1.07 101.3 %  ± 0.897544  
C 809.6  ± 1.57 101.34 % ± 3.264 
D 812.5  ± 1.70 100.30 % ± 3.607  
E 842.7  ± 3.6 101.40 % ± 0.3778 
 
 
Figure 2. Comparison of different brands weight variation of different brands of 
ciprofloxacin tablets. 
 
3.3. Content Uniformity (Assay) 
Every unit of tablet should contain the amount of drug substance equivalent to its label 
amount. For the evaluation of content, assay should be performed. The weight variation test is 
simplified and alternative to content uniformity test to assure therapeutic utility [10] and is an 
indicator of variations in the drug content [11]. The average chemical content (assay) values of the 
different brands of ciprofloxacin tablets tested shown in table 2 and figure 3. The results of the 
assay of chemical content of ciprofloxacin tablets showed that the active content of all the brands 
were between 98.10  2.2990 % (A brand) and 101.40  0.3778 % (E brand) of the labeled amount 
specified for ciprofloxacin tablets. A and B brands were chemically equivalent because they had 
chemical content not less than 90 % and not more than 100 % (w/w) [12]. According to the United 
State Pharmacopoeia [13], ciprofloxacin tablets should contain not less than 90 % and not more 
than 110 % of ciprofloxacin tablets. The results indicated that although different manufacturer 
formulates the different brands are under the BP/USP specification [14]. Furthermore, all the 
  
brands of the tablets passed the test for the content of ciprofloxacin tablets. All these brands fall 
within the British Pharmacopoeia Specification of 95 % – 105 % [15]. 
 
 
Figure 3. Comparison of assay content (Percent %) of different brands of ciprofloxacin tablets. 
 
3.4. Hardness Test: 
The crushing strength of the tablets is an essential criterion in the determination of the 
ability of the tablets to resist chipping, abrasion or breakage under conditions of storage, 
transportation and handling before storage [16]. Hardness, which is now more appropriately called 
crushing strength of the tablet is determined to make adjustments to the pressure in the tablet press 
[17]. It can also influence other parameters such as friability and disintegration [18].   
The average values of hardness of the different brands of ciprofloxacin tablets tested shown 
in table 3 and figure 4. Average hardness was found in the range of 20.03 kg/cm
2 
(A brand) to 
31.535 kg/cm
2
 (E brand). The results indicated that all brands of ciprofloxacin tablets were not in 
the limit range of between 4 to 10 kg/cm
2 
stated [ [17, 19]. Where all brands were greater than 20 
kg/cm
2
. The hardness of the tablets showed that all brands gave the highest crushing strength.  
Hardness is referred to as non-compendial test.  The hardness or crushing strength assesses 
the ability of tablets to withstand handling without fracturing or chipping. It can also influence 
other parameters such as friability and disintegration. Normally, a force of about 4 kgs is the 
minimum requirement for satisfactory tablets [20]. Therefore, the tablets of all products were 
satisfactory for hardness. 
Table 3. Hardness (kg/cm
2
), % deviation from hardness, friability percent (%) , 
disintegration time (min), dissolution (30 min), % deviation from dissolution of different 
brands of ciprofloxacin tablets.     
Brands 
Hardness (kg/cm
2
)   
 % RSD   
Friability  
(%)    
Disintegration 
time (min) 
Dissolution (30 min),  
% RSD 
A 20.03 (±14.397) 0.36 1.41 99.33 (±2.03711) 
B 27.41 (±7.98681) 0.37 3.16 100.15 (±1.4314) 
C 25.585 (±8.3994) 0.12 3.51 98.15 (±1.796) 
D 23.35 (±8.16783) 0.013  1.41 96.4 (±1.16786) 
E 31.535 (±7.37343) 0.06 4.15 98.00 (±1.2712) 
 
  
 
 
 
Figure 4. Comparison of hardness of different brands of ciprofloxacin tablets. 
 
3.5. Friability Test: 
Tablet hardness is not the absolute indicator of the tablet strength since some formulations 
when compressed to very hard tablet tend to cap or laminate on attrition losing their crown part. 
Therefore, another measure of the tablet strength, its friability is often measured. The loss due to 
abrasion is a measure of the tablet friability. The average values of friability of the different brands 
of ciprofloxacin tablets tested shown in table 3 and figure 5. The average values of friability 
ranging from 0.01 % (D brand) to 0.37 % (B brand). The friability was less than 0.5 %, indicating 
that it is within the compendia limits, which showed that the tablets possess good mechanical 
strength. Also, this showed that all the brands could withstand abrasion without loss of tablet 
integrity, and the causes of high friability were taken in consideration during manufacturing the 
tablet. Namely tablets compressed with larger force tend to have slightly lower friability compared 
with the ones compressed with smaller force [21]. The pharmacopoeia [20] states that the friability 
value of tablets should be less than 1% and as such all the brands of ciprofloxacin had passed this 
friability specification 
 
Figure 5. Comparison of friability percent (%) for different brands of ciprofloxacin tablets. 
 
  
3.6. Disintegration Time: 
Tablet disintegration time is one of the very important physicochemical properties in solid 
dosage forms. The disintegration test measures the time required for tablets to disintegrate into 
particles. This is a necessary condition for dissolution and could be the rate-determining step in the 
process of drug absorption. The average values of disintegration of the different brands of 
ciprofloxacin tablets tested shown in table 3 and in figure 6. The results of disintegration time 
(min) of ciprofloxacin tablets were ranging from 1.41 min (A and D brans) to 4.15 min (E brand). 
All brands of the ciprofloxacin tablets passed the pharmacopoeia [22] standard which stipulates a 
disintegration time of not more than 15 minutes for uncoated tablets, while USP  specification for 
disintegration is 30 min both for uncoated and film coated  tablets. All the brands were complied 
with the both BP and USP specifications. All the brands were complied with the both BP and USP 
specifications. The rapid disintegration time exhibited by all the brands might be due to type and 
amount of disintegrant used in the formulation. All the disintegration times had fallen within the 
acceptable range.    
 
 
Figure 6. Comparison of disintegration time (min) of different brands of ciprofloxacin tablets. 
 
3.7. Dissolution Test 
The process of dissolution plays a vital role in liberation a drug from its dosage form and 
making it available for subsequent gastrointestinal absorption. So, dissolution analysis of 
pharmaceutical solid dosage forms is a very important test of product quality and it can be used as 
a sensitive method for differentiating between formulations of the same therapeutic agent [23 – 
24]. 
Drugs with poor dissolution profile will not be available in the body system to elicit 
therapeutic effect [25]. Also, the dissolution study was carried out to determine the resistance of 
the materials the acidic environment of the stomach and their suitability as enteric coating 
materials. The drug release study is a measure of the amount of the drug released into the 
dissolution medium with time. This study gives an idea of amount of drug available for absorption 
after oral administration. Drugs with poor dissolution profile will not be available in the body 
system to elicit therapeutic effect [25].  
The average values of dissolution of the different brands of ciprofloxacin tablets tested 
shown in table 3 and graphically in figure 7. The obtained dissolution content at 30 minutes was 
found to be ranged from 96.48 %   1.168 % to 100.15 %  1.4314 %. All brands of ciprofloxacin 
tablets showed more than 90 % drug release after 30 minutes. At 30 mins, all the brands released 
more than the pharmacopoeia (USP 30, NF 25) requirement of 70 % active pharmaceutical 
ingredient [20]. All the brands of the ciprofloxacin hydrochloride tablets complied with the official 
  
specification for content uniformity having between 92-104% as stipulated by the USP. This might 
be as a result of strict adherence to good manufacturing practice in the process of manufacturing 
these tablets. 
 
 
Figure 7. Comparison of dissolution test of different brands ciprofloxacin tablets. 
 
Conclusion  
From the present study, it was clearly demonstrated that all five brands of the ciprofloxacin 
hydrochloride tablet comply with BP and USP specifications for in vitro quality control tests of 
uniformity of weight, uniformity of content, friability, disintegration time, and dissolution except 
hardens test for five brands. The USP and BP specification of maximum hardens value of 10 
kg/cm
2
, where the lower value of hardens is 20.03 kg/cm
2
 and the value is 31.535 kg/cm
2
. But 
Hardness is referred to as non-compendial test.  
Finally, bioequivalence studies are essential and important. Also such studies may be more 
important in developing countries where counterfeit and substandard drugs have become a major 
challenge to health care services. 
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